<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940627-0-00253</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (5)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Positive control group. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  A single concentration of a  <!-- PJG 0012 frnewline --> compound known to produce SCEs  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  is adequate as a positive  <!-- PJG 0012 frnewline --> control if it shows a significant response at any one time point;  <!-- PJG 0012 frnewline --> additional concentration levels may be used. To select an  <!-- PJG 0012 frnewline --> appropriate concentration level, a pilot or trial study may be  <!-- PJG 0012 frnewline --> advisable. Initially, one concentration of the test substance  <!-- PJG 0012 frnewline --> may be used, the maximum tolerated dose or that producing some  <!-- PJG 0012 frnewline --> indication of toxicity as evidenced by animal morbidity  <!-- PJG 0012 frnewline --> (including death) or target cell toxicity. Intraperitoneal  <!-- PJG 0012 frnewline --> injection of 1,2-dimethyl-benz-anthracene or benzene are examples  <!-- PJG 0012 frnewline --> of positive control exposures. A concentration of 50&hyph;80 percent  <!-- PJG 0012 frnewline --> of an LD50 would also be a suitable guide.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (6)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Inhalation exposure. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) All data developed within this study shall be in  <!-- PJG 0012 frnewline --> accordance with good laboratory practice provisions under &sect; <!-- PJG 0012 frnewline --> 79.60.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (ii) The general conduct of this study shall be in  <!-- PJG 0012 frnewline --> accordance with the vehicle emissions inhalation exposure  <!-- PJG 0012 frnewline --> guideline in &sect;79.61.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Test performance_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treatment. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  At the conclusion of the exposure period,  <!-- PJG 0012 frnewline --> all test animals are anaesthetized and heart punctures are  <!-- PJG 0012 frnewline --> performed. Lymphocytes are isolated over a Ficoll gradient and  <!-- PJG 0012 frnewline --> replicate cell cultures are started for each animal. After some  <!-- PJG 0012 frnewline --> 21 hours, the cells are treated with BrdU and returned to  <!-- PJG 0012 frnewline --> incubation. The following day, a spindle inhibitor (e.g.,  <!-- PJG 0012 frnewline --> colchicine) is added to arrest cell growth in c-metaphase. Cells  <!-- PJG 0012 frnewline --> are harvested 4 hours later and second-division metaphase cells  <!-- PJG 0012 frnewline --> are washed and fixed in methanol:acetic acid, stained, and  <!-- PJG 0012 frnewline --> chromosome preparations are scored for SCEs.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Staining method. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Staining of slides to reveal SCEs can  <!-- PJG 0012 frnewline --> be performed according to any of several protocols. However, the  <!-- PJG 0012 frnewline --> fluorescence plus Giemsa method is recommended.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Number of cells scored. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) A minimum of 25 well-stained, second-division metaphase  <!-- PJG 0012 frnewline --> cells shall be scored for each animal for each cell type.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) At least 100 consecutive metaphase cells shall be  <!-- PJG 0012 frnewline --> scored for the number of first, second, and third division  <!-- PJG 0012 frnewline --> metaphases for each animal for each cell type.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii) At least 1000 consecutive PBL's shall be scored for  <!-- PJG 0012 frnewline --> the number of metaphase cells present.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iv) The number of cells to be analyzed per animal shall be  <!-- PJG 0012 frnewline --> based upon the number of animals used, the negative control  <!-- PJG 0012 frnewline --> frequency, the pre-determined sensitivity and the power chosen  <!-- PJG 0012 frnewline --> for the test. Slides shall be coded before microscopic analysis.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> (e)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Data and report_ <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Treatment of results. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  In addition to the reporting  <!-- PJG 0012 frnewline --> requirements specified under &sect;&sect;79.60 and 61, data shall be  <!-- PJG 0012 frnewline --> presented in tabular form, providing scores for both the number  <!-- PJG 0012 frnewline --> of SCE for each metaphase. Differences among animals within each  <!-- PJG 0012 frnewline --> group shall be considered before making comparisons between  <!-- PJG 0012 frnewline --> treated and control groups.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Statistical evaluation. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Data shall be evaluated by  <!-- PJG 0012 frnewline --> appropriate statistical methods.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline -->  (3)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Interpretation of results. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  (i) There are several criteria for determining a positive  <!-- PJG 0012 frnewline --> result, one of which is a statistically significant dose-related  <!-- PJG 0012 frnewline --> increase in the number of SCE. Another criterion may be based  <!-- PJG 0012 frnewline --> upon detection of a reproducible and statistically significant  <!-- PJG 0012 frnewline --> positive response for at least one of the test concentrations.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (ii) A test substance which does not produce either a  <!-- PJG 0012 frnewline --> statistically significant dose-related increase in the number of  <!-- PJG 0012 frnewline --> SCE or a statistically significant and reproducible positive  <!-- PJG 0012 frnewline --> response at any one of the test concentrations is considered not  <!-- PJG 0012 frnewline --> to induce rearrangements of DNA segments in this system.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (iii) Both biological and statistical significance shall be  <!-- PJG 0012 frnewline --> considered together in the evaluation.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            